XDH and diabetic kidney disease: The study utilized a streptozotocin (STZ)-induced mouse model of DKD and high glucose (HG)-treated human glomerular endothelial cells (GECs) to evaluate febuxostat, an XO inhibitor across physical, biochemical, and molecular parameters.